ANXV
Retinal Vein Occlusion (RVO)
Key Facts
About Annexin Pharmaceuticals
Annexin Pharmaceuticals is a clinical-stage biotech with a mission to 'empower the body to fight disease' by targeting phosphatidylserine (PS) exposure, a root pathological mechanism. Its lead asset, ANXV, is a recombinant human Annexin A5 protein currently in a Phase 2a proof-of-concept study for Retinal Vein Occlusion (RVO), with preclinical work ongoing in oncology. The company's strategy is to de-risk and optimize the ANXV program's value through clinical validation in RVO before seeking partnerships or licensing deals to expand into larger indications like cancer and cardiovascular diseases.
View full company profileAbout Annexin Pharmaceuticals
Annexin Pharmaceuticals is a clinical-stage biotech with a mission to 'empower the body to fight disease' by targeting phosphatidylserine (PS) exposure, a root pathological mechanism. Its lead asset, ANXV, is a recombinant human Annexin A5 protein currently in a Phase 2a proof-of-concept study for Retinal Vein Occlusion (RVO), with preclinical work ongoing in oncology. The company's strategy is to de-risk and optimize the ANXV program's value through clinical validation in RVO before seeking partnerships or licensing deals to expand into larger indications like cancer and cardiovascular diseases.
View full company profileAbout Annexin Pharmaceuticals
Annexin Pharmaceuticals is a clinical-stage biotech with a mission to 'empower the body to fight disease' by targeting phosphatidylserine (PS) exposure, a root pathological mechanism. Its lead asset, ANXV, is a recombinant human Annexin A5 protein currently in a Phase 2a proof-of-concept study for Retinal Vein Occlusion (RVO), with preclinical work ongoing in oncology. The company's strategy is to de-risk and optimize the ANXV program's value through clinical validation in RVO before seeking partnerships or licensing deals to expand into larger indications like cancer and cardiovascular diseases.
View full company profileAbout Annexin Pharmaceuticals
Annexin Pharmaceuticals is a clinical-stage biotech with a mission to 'empower the body to fight disease' by targeting phosphatidylserine (PS) exposure, a root pathological mechanism. Its lead asset, ANXV, is a recombinant human Annexin A5 protein currently in a Phase 2a proof-of-concept study for Retinal Vein Occlusion (RVO), with preclinical work ongoing in oncology. The company's strategy is to de-risk and optimize the ANXV program's value through clinical validation in RVO before seeking partnerships or licensing deals to expand into larger indications like cancer and cardiovascular diseases.
View full company profileAbout Annexin Pharmaceuticals
Annexin Pharmaceuticals is a clinical-stage biotech with a mission to 'empower the body to fight disease' by targeting phosphatidylserine (PS) exposure, a root pathological mechanism. Its lead asset, ANXV, is a recombinant human Annexin A5 protein currently in a Phase 2a proof-of-concept study for Retinal Vein Occlusion (RVO), with preclinical work ongoing in oncology. The company's strategy is to de-risk and optimize the ANXV program's value through clinical validation in RVO before seeking partnerships or licensing deals to expand into larger indications like cancer and cardiovascular diseases.
View full company profile